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Abstract
Introduction: The growth of a tumour is limited by its neovascularisation. Angiogenesis is dependent on a dynamic balance between its
activators and inhibitors. One of the most important antiangiogenic factors is endostatin.
The aim of the study was to assess the usefulness of serum endostatin levels as a potential marker of metastases of well-differentiated
thyroid cancer, and to estimate the effect of endogenous TSH stimulation on serum endostatin levels.
Material and methods: The study group consisted of 68 patients with differentiated thyroid cancer. We provided a cross-sectional analy-
sis of the study group divided into patients with distant and/or locoregional metastases and patients with remission, and compared it with
serum endostatin levels of healthy volunteers. Serum endostatin concentration was measured by ELISA kits (R&D Systems).
Results: Median endostatin concentration was significantly higher in patients with distant metastases than in patients with remission (141.95
v. 105.345 ng/ml, p < 0.05). This was not observed in patients with locoregional metastases. Serum endostatin levels were significantly higher
in the study group, including patients with remission, than in the control group of healthy volunteers (remission v. healthy median 105.3 v.
88.1 ng/ml, p < 0.05). During endogenous TSH stimulation, endostatin levels significantly decreased (122.94 v. 93.60 ng/ml, p < 0.05).
Conclusions: The study indicates that endogenous TSH stimulation plays a role in the regulation of endostatin secretion. Although
median serum endostatin levels are higher in patients with distant metastases than in patients with remission, its clinical usefulness is
limited due to the overlapping data between the study groups. (Pol J Endocrinol 2010; 61 (1): 7–12)
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Streszczenie
Wstęp: Wzrost nowotworów jest zależny od stopnia ich unaczynienia. Angiogeneza jest zależna od dynamicznej równowagi między jej
aktywatorami i inhibitorami. Jednym z najważniejszych czynników antyangiogennych jest endostatyna.
Celem pracy była ocena przydatności pomiaru stężenia endostatyny w surowicy krwi, jako potencjalnego wskaźnika obecności przerzu-
tów zróżnicowanego raka tarczycy oraz oszacowanie wpływu endogennej stymulacji hormonu tyreotropowego (TSH, thyroid stimulating
hormone) na stężenie endostatyny w surowicy.
Materiał i metody: Grupa badana składała się z 68 pacjentow ze zróżnicowanym rakiem tarczycy. Przeprowadzono analizę przekrojową
stężenia endostatyny w surowicy krwi pacjentów, którzy w wyniku zastosowanego leczenia uzyskali remisję w porównaniu z jej stęże-
niem u chorych z przerzutami lokoregionalnymi i odleglymi. Stężenie endostatyny oznaczono za pomocą testów ELISA R&D Systems.
Wyniki: Średnie stężenie endostatyny było znamiennie wyższe u chorych z przerzutami odleglymi raka tarczycy niż u pacjentów
w remisji (141,95 v. 105,345 ng/ml, p < 0,05). Stężenie endostatyny nie różniło się istotnie między chorymi z przerzutami lokoregionalnymi
i pacjentami w remisji.
Stężenia endostatyny były znamiennie wyższe w całej grupie badanej, w tym u pacjentów w remisji, w porównaniu ze stężeniem stwier-
dzonym u zdrowych ochotnikow (mediana remisja v. zdrowi 105,3 v. 88,1 ng/ml, p < 0,05). W czasie endogennej stymulacji TSH stężenie
endostatyny znamiennie się zmniejszyło (122,94 v. 93,60 ng/ml, p < 0,05).
Wnioski: Endogenna stymulacja TSH bierze udział w regulacji wydzielnia endostatyny. Stężenie endostatyny jest znamiennie wyższe
u chorych z przerzutami odległymi raka tarczycy w porównaniu z pacjentami w remisji. Obserwacja ta ma jednak ograniczone znaczenie
kliniczne, ponieważ nie można ustalić wartości progowej stężenia endostatyny wskazującej na obecność przerzutów odleglych.
(Endokrynol Pol 2010; 61 (1): 7–12)
Słowa kluczowe: endostatyna, rak tarczycy, przerzuty, stymulacja TSH
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Introduction
Angiogenesis is an important process involved in the
growth of normal and neoplastic tissues [1]. New blo-
od vessel formation depends on a dynamic balance be-
tween the activators and inhibitors of angiogenesis. The
factors involved in this process are potential markers of
tumour spread and consequently are possible targets
for therapy. The activated endothelial cells required for
angiogenesis are theoretically free of drug resistance,
in contrast to the cancer cells rapidly changing due to
genomic instability.
One of the most potent inhibitors of neoangiogene-
sis is endostatin — a 20 kDa internal fragment of the
carboxy terminus of collagen XVII. This small protein
acts widely in the regulation of the angiogenesis —
mainly suppressing pathological angiogenesis and ha-
ving little or no activity against wound healing or re-
production [1]. There is an evidence that 12% of all hu-
man genes are significantly regulated in human micro-
vascular endothelial cells exposed to endostatin [2, 3].
Therefore, endostatin represents a broad-spectrum
inhibitor of angiogenesis which could be used in the
therapy of cancer. In fact, endostatin has been registe-
red in China for the treatment of non-small cell lung
cancer [4].
So far, little is known about the expression of endo-
statin in well-differentiated thyroid cancer and its po-
tential usefulness as a prognostic factor [5, 6]. To our
knowledge, there are no data describing serum endo-
statin levels in patients with thyroid cancer. The esti-
mation of serum endostatin levels is very simple and
more useful for clinicians in contrast to the measure-
ment of tissue expression which demands complicated
immunohistochemical procedures.
Furthermore, there are no data regarding the influ-
ence of endogenous TSH stimulation on serum endosta-
tin levels. Therefore, our aim is to study whether:
— serum endostatin concentrations differ between pa-
tients with metastatic and non-metastatic well-dif-
ferentiated thyroid cancer;
— serum endostatin levels in patients with remission
are similar to those in healthy subjects;
— endogenous TSH stimulation results in a change in
serum endostatin concentration in patients with dif-
ferentiated thyroid cancer.
Material and methods
Inclusion and exclusion criteria
The study protocol was approved by the Ethical Com-
mittee of the Collegium Medicum in Bydgoszcz, Nicolaus
Copernicus University in Torun, Poland. All the patients
gave informed consent.
The study included 68 patients treated in the Depart-
ment of Endocrinology and Diabetology of the Nicolaus
Copernicus University in Bydgoszcz in the years 2003–2006.
The inclusion criteria for the study were as follows:
1. Well-differentiated thyroid cancer after total or near
total thyroidectomy.
2. Radioactive iodine ablation.
3. No other known malignancies.
4. Normal platelet count.
The exclusion criteria were as follows:
1. Diabetes mellitus,
2.  Heart failure,
3. Abnormal platelet count — because of its potential
effect on serum endostatin concentration.
The study group underwent the standard follow-up
procedure:
— diagnostic WBS, Tg, anti-Tg antibodies, ultrasono-
graphy (USG) of the neck after endogenous TSH sti-
mulation (TSH > 30 uIU/ml), 7–8 months after 131-I
treatment;
— frequency of the same procedure — in the case of
full remission: in low risk patients after 2 years, then
every 5 years, in high risk patients — every year. In
patients with persistent/recurrent disease — 7–8 mon-
ths after the additional treatment with radioiodine;
— systematic physical examination, TSH and Tg me-
asurements every 6 months during TSH suppres-
sion (TSH <0,1 uIU/ml).
Remission was defined as:
1. Tg levels during TSH stimulation less than 2 ng/ml.
2. Absence of anti-Tg antibodies.
3. Negative WBS with 24-hour uptake less than 0.1%.
4. Normal results of standard imaging procedures:
USG of the neck, X-ray of the chest, or any other
(CT, NMR, PET, if needed).
The study included a control group of 25 healthy
volunteers, comparable in age and sex with the study
group.
The inclusion criteria for the control group:
1. Normal USG of the neck.
2. TSH, platelet count within normal range.
3. No evidence of chronic or acute disease.
Serum samples
Blood samples were obtained as a part of the routine
clinical evaluations (TSH, Tg, anti-Tg antibodies, blood
morphology). Thirty minutes after donation, they were
centrifuged for 15 minutes at 2500 × g. The serum was
removed immediately, and stored at < –80oC.
Serum endostatin measurements
Serum endostatin measurements were performed in
batches using the Quantikine human endostatin san-
dwich enzyme immunoassay technique (R&D Systems,
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Minneapolis, MN). All assays were performed in dupli-
cate.
Serum Tg measurements
Serum Tg was measured with an IRMA assay (LIAISON,
Dia Sorin, Italy).
Detection limits — < 0.2 ng/ml
Reference values assuming patients with an intact thy-
roid — 0.2–70 ng/ml
Serum anti-Tg antibodies measurements
Serum anti-Tg antibodies were measured with an IRMA
assay (LIAISON, Dia Sorin, Italy).
Detection limits: < 5 IU/ml
Reference values: 5–100 IU/ml.
Serum TSH measurements
Serum TSH was measured with an ultrasensitive
CMIA assay (ARCHITECT YOU 8200, ABBOTT). De-
tection limits: < 0.0025 uIU/ml Reference values:
0.35–4.94 uIU/ml.
Statistical analysis
Normally distributed data were presented as mean
± SD. Data not normally distributed were presented as
median values. For normally distributed data, the Stu-
dent t-test was used. Nonparametric tests were used
when the data was not normally distributed. The gro-
ups were compared using U Mann-Whitney’s test or
ANOVA Kruskal-Wallis’ test. Relationships among
variables were sought using Spearman’s correlation co-
efficient. Paired data were analysed using Wilcoxon’s
test. Statistical significance was assumed when the
P value was less than or equal to 0.05.
Results
Baseline serum samples were obtained from 68 patients
— 59 women and 9 men.
The mean age at the time of the study was 44. 9 ±
± 12.3 years, the mean duration of the disease was 53.3 ±
± 45.8 months. Paired samples (during suppression
and after endogenous TSH stimulation) were availa-
ble from 34 patients, according to the follow-up pro-
cedures.
Histological classification revealed 46 (68%) papilla-
ry thyroid cancers, 18 (26%) follicular thyroid cancers,
and 4 (6%) oxyphilic thyroid cancers.
Within the group, 54 (79.4%) patients reached the
remission criteria. The remaining 14 (20.6%) patients
showed biochemical and morphological evidence of
metastatic disease.
Serum endostatin levels were not dependent on age,
sex, histological type of cancer, duration of the disease,
number of radioiodine doses, TSH levels during sup-
pression, or the total dose of 131-I used in the treatment.
The concentrations of endostatin in each group are
presented in Table I.
Serum endostatin concentration was significantly
higher in patients with distant metastases of the thyro-
id cancer than in patients with locoregional ones, pa-
tients in remission, or healthy subjects (Fig. 1).
Serum endostatin concentrations in patients with
locoregional metastases did not significantly differ from
patients with remission and healthy people (Fig. 1).
The location of distant metastases and serum endo-
statin, Tg and TSH levels during suppression and sti-
mulation are presented in Table II.
Patients with remission had higher endostatin con-
centrations than healthy people (Fig. 1).
During endogenous TSH stimulation provided in
34 patients with thyroid cancer, endostatin levels signi-
Table I. Serum endostatin concentrations in each study group
Tabela I. Stężenia endostatyny w badanych grupach
Endostatin [ng/ml] n Median Min. Max.
Remission 52 105.3 62.4 330.9
suppression
Locoregional 7 92.71 71.23 172.75
metastases
suppression
Distant 7 141.95 119.17 179.04
metastases
suppression
Healthy 25 88.1 44.4 116.6
Figure 1. Serum endostatin levels in patients with distant
metastases (DM), locoregional metastases (LM), in remission (R),
and healthy people (H)
Rycina 1. Stężenia endostatyny u pacjentów z przerzutami
odległymi (DM), lokoregionalnymi (LM), w remisji (R) i u zdrowych
osób (H)
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ficantly decreased (Fig. 2). This was observed in meta-
static as well as non-metastatic patients.
Discussion
This study has demonstrated that patients with distant
metastases have significantly higher median serum en-
dostatin levels than patients with remission. However,
patients with only locoregional metastases did not de-
monstrate increased serum endostatin levels compared
with those with remission. Additionally, serum endo-
statin levels were higher in patients free of disease after
the treatment than in healthy people. These observa-
tions suggest that endostatin plays a role in thyroid can-
cer biology.
Nevertheless, the clinical usefulness of endostatin
as a marker of distant metastases is limited because there
are overlapping data between the observed subgroups.
Although endostatin levels in all patients with distant
metastases were greater then median values in patients
with remission and maximum values in healthy sub-
jects, still the interpretation of high levels of endostatin
is difficult. For example the highest value (330.9 ng/ml)
was observed in a patient with no evidence of metastatic
disease (Table I).
There is an interesting observation that patient
2 with non-iodine avid metastases, and patients 4, 5,
and 7 (Table II) with relatively low Tg levels based on
the extent of the disease, suggesting partial de-differen-
tiation of their tumours, had very similar endostatin le-
vels. Potentially, the use of endostatin as a disease mar-
ker in patients with tumours that do not efficiently make
Tg would be useful, but requires further investigation.
 To the best of our knowledge, there are no data
describing serum endostatin levels in patients with well-
differentiated thyroid cancer. There are several reports
underlying the usefulness of measurements of serum
Table II. Serum VEGF, Tg, and TSH levels during suppression and stimulation in patients with distant metastases
Tabela II. Stężenia VEGF, Tg i TSH w surowicy w czasie supresji i stymulacji u pacjentów z przerzutami odległymi
TNM staging at Location of Endostatin Endostatin Tg Tg TSH TSH
the diagnosis metastases suppression stimulation suppression stimulation suppression stimulation
[ng/ml] [ng/ml] [ng/ml] [ng/ml] [uIU/ml] [uIU/ml]
Follicular IV Bones — > 20 foci 179.04 120.07 10.8 228.4 0.063 38.236
Papillary II Non-iodine 138.45 13.6 0.015
absorbing —
mediastinum
3 foci,
thyroid bed — 1 focus
Papillary III Lungs — 9 foci 120.45 91.93 Anti-Tg (+) Anti-Tg (+) 0.013 68.300
Follicular II Lungs — 4 foci, 141.95 12.8 56.7 0.002 35.500
thyroid bed
— 1
focus 4 cm
Papillary II Lungs — 12 foci 142.22 95.26 4.9 16.8 0.025 44,800
Follicular IV Non-iodine avid 171.3 9615 0.025
— multiple to
hepar, bones,
skin, left kidney
Papillary II Multiple 142.22 95.26 4.88 16.8 0.03
micrometastases
to the lungs
Figure 2. Serum endostatin levels after TSH suppression and
endogenous stimulation
Rycina 2. Stężenia endostatyny w trakcie supresji TSH oraz
endogennej stymulacji TSH
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endostatin levels as a prognostic marker in gastric, he-
patocellular carcinoma, renal cancer, non-Hodgin’s lym-
phoma, and non-small cell lung cancer [7–11]. The hi-
gher serum endostatin levels in the studies presented
above were correlated with advanced clinical stage of
disease and poorer outcome.
There are very limited data relating to endostatin
tissue expression in well-differentiated thyroid cancer.
Hoffmann et al. demonstrated higher endostatin expres-
sion in primary tumor and metastatic lesions derived
from human thyroid cancer compared to normal thy-
roid tissue, suggesting a possible association with tu-
mor progression [5].
Given the antiangiogenic potential of endostatin,
involved in a defence mechanism against further tu-
mor growth, it is surprising that its high serum concen-
tration is associated with metastatic disease.
There is evidence that antiangiogenic and antitumor
activity of endostatin reveals a U-shaped curve with
a specific optimal range responsible for higher activity
[12, 13]. The theoretical explanation is that serum en-
dostatin levels in patients with distant metastases,
a more progressive disease, are not optimally active. The
other possible explanation is that the dynamic balance
between pro- and anti-angiogenic factors is still swit-
ched to proangiogenic activity. There are studies docu-
menting the higher vascular endothelial growth factor
(VEGF — the potent proangiogenic factor) levels in
metastatic well-differentiated thyroid cancer [14–16].
The correlation between VEGF and endostatin levels
was observed in different malignancies: renal cell car-
cinoma, colorectal cancer with liver metastases, non-
Hodgin’s lymphoma, and breast cancer [10, 17–19].
To the best of our knowledge, we report for the first
time that endogenous TSH stimulation results in a de-
crease in serum endostatin levels. A possible theoreti-
cal explanation is that the most potent stimulus of well-
differentiated thyroid cancer — TSH acts by decreasing
the antiangiogenic defence mechanism. We observed
significant decrease in serum endostatin levels in the
whole study group, even in patients with remission
— without the clinical and biochemical evidence of di-
sease. These observations suggest that TSH might re-
gulate endostatin synthesis through receptors located
not only in follicular thyroid cells. The expression of
TSH-receptors in tissues other than the thyroid gland
was confirmed by Sorisky et al. [20].
The other possible explanation of the decrease in
serum endostatin levels after TSH stimulation is the
specific method of stimulation — the withdrawal of
L-thyroxine. There is growing evidence that thyroid
hormones are proangiogenic [21–24]. This effect is mem-
brane-initiated at a hormone receptor site on the inte-
grin aVb3 [25]. The decreased level of L-thyroxine (T4)
could lead to the inhibition of angiogenesis. There are
data describing lower levels of angiogenesis stimula-
tors, like VEGF, after T4 withdrawal, so consequently,
the lower endostatin levels observed in the present stu-
dy may reflect the switch of the pro-/anti-angiogenic
balance to the lower set-point [14, 26]. Another possible
reason for the decrease in endostatin levels in whole
study group is hypothyreosis after withdrawal of L-T4
interpreted as an additional disease which might have
influenced the angiogenesis. In fact, such lower endo-
statin levels in hypothyroidism have been previously
described [27].
Conclusions
1. Median serum endostatin levels are higher in pa-
tients with distant metastases of thyroid cancer
than in patients with locoregional metastases and
patients in remission. The clinical usefulness of this
finding is limited due to the overlapping data and
the lack of a direct cut-off point indicating meta-
static disease.
2. Endogenous TSH stimulation results in a decrease
in serum endostatin levels in patients with or wi-
thout thyroid cells, suggesting its regulatory effects
through receptors located outside the thyrocytes.
3. Serum endostatin levels are not dependent on age,
sex, histological type of cancer, duration of the dise-
ase, number of radioiodine doses, or the total dose
of 131-I used in the treatment.
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